GLP-1 Medications for Heart Disease Prevention: How Ozempic and Wegovy Reduce Cardiovascular Risk

By UTCardiothoracicSurgery.com Editorial Team

By UTCardiothoracicSurgery.org Editorial Team

The discovery that medications initially developed for diabetes and weight loss also dramatically reduce heart attacks, strokes, and cardiovascular death represents one of the most significant advances in preventive cardiology in recent decades. GLP-1 receptor agonists, particularly semaglutide (marketed as Ozempic and Wegovy), have demonstrated cardiovascular benefits that extend far beyond their effects on blood sugar and body weight.

For patients with established cardiovascular disease, obesity, or type 2 diabetes, understanding how GLP-1 medications protect the heart and which patients benefit most can inform important treatment decisions. This comprehensive analysis examines the clinical evidence for cardiovascular protection, the mechanisms through which GLP-1 medications improve heart health, and how to determine if these medications are appropriate for your cardiovascular risk profile.

Secondary findings: Breaking down the composite endpoint into individual components:

• Cardiovascular death: 2.5% with Wegovy vs. 2.8% with placebo (not statistically significant)
• Nonfatal heart attack: 2.7% with Wegovy vs. 3.7% with placebo (28% reduction, statistically significant)
• Nonfatal stroke: 1.5% with Wegovy vs. 1.8% with placebo (not independently significant)

The overall cardiovascular benefit appeared driven primarily by reduction in heart attacks rather than strokes or cardiovascular death, though the trend favored Wegovy across all components.

The SUSTAIN-6 Trial: Ozempic's Cardiovascular Evidence

The SUSTAIN-6 trial, published in 2016, established semaglutide's cardiovascular benefits in patients with type 2 diabetes.

Study design: The trial enrolled 3,297 patients with type 2 diabetes at high cardiovascular risk (established cardiovascular disease or chronic kidney disease, or age 60+ with cardiovascular risk factors). Participants received either Ozempic (semaglutide 0.5mg or 1mg weekly) or placebo for approximately 2 years.

Results: Ozempic reduced the risk of major cardiovascular events by 26% compared to placebo:

• Cardiovascular events occurred in 6.6% of Ozempic patients vs. 8.9% of placebo patients
• Nonfatal stroke risk decreased significantly (39% reduction)
• Nonfatal heart attack showed a trend toward reduction but didn't reach statistical significance
• Cardiovascular death was similar between groups

Additional finding: Ozempic significantly reduced the progression of diabetic kidney disease, with 36% lower risk of new or worsening nephropathy. This kidney protection contributed to Ozempic's recent FDA approval for reducing kidney disease progression in adults with type 2 diabetes and chronic kidney disease.

Comparing Cardiovascular Outcomes Across GLP-1 Medications

Multiple GLP-1 medications beyond semaglutide have demonstrated cardiovascular benefits in clinical trials:

Liraglutide (Victoza): The LEADER trial showed 13% reduction in cardiovascular events in patients with type 2 diabetes and high cardiovascular risk.

Dulaglutide (Trulicity): The REWIND trial demonstrated 12% reduction in cardiovascular events in patients with type 2 diabetes.

Tirzepatide (Mounjaro/Zepbound): While tirzepatide shows superior weight loss and glycemic control compared to semaglutide, dedicated cardiovascular outcomes trials are still ongoing. Cardiovascular data will emerge from the SURPASS-CVOT trial, expected to report results in 2025-2026.

Semaglutide currently has the strongest cardiovascular evidence base, particularly for patients with obesity and established cardiovascular disease who don't have diabetes (SELECT trial). For patients with type 2 diabetes and cardiovascular risk, multiple GLP-1 options have proven cardiovascular benefits.

Understanding the Mechanisms: How GLP-1 Medications Protect the Heart

The cardiovascular benefits of GLP-1 medications emerge through multiple complementary mechanisms. Unlike medications that target a single pathway (such as statins lowering cholesterol or blood pressure drugs reducing vascular resistance), GLP-1 receptor agonists affect numerous cardiovascular risk factors simultaneously.

Weight Loss and Metabolic Improvement

The substantial weight loss produced by GLP-1 medications contributes significantly to cardiovascular benefit, though it doesn't fully explain the observed effects.

Weight reduction effects on cardiovascular risk:

• Every 5kg (11 pounds) of weight loss reduces systolic blood pressure by approximately 2-4 mmHg
• Weight loss improves insulin sensitivity, reducing metabolic stress on the cardiovascular system
• Visceral adipose tissue (fat around organs) decreases more than subcutaneous fat, reducing inflammatory signals that promote atherosclerosis
• Weight-related strain on the heart decreases, improving cardiac function and reducing heart failure risk

In the SELECT trial, participants on Wegovy lost an average of 9.4% of body weight compared to 0.9% with placebo. While weight loss accounted for some of the cardiovascular benefit, statistical analyses suggest it explains only about 40-50% of the risk reduction. Other mechanisms must be contributing.

Blood Pressure Reduction

GLP-1 medications consistently lower blood pressure, even independent of weight loss effects.

Typical blood pressure reductions:

• Systolic blood pressure: 3-5 mmHg decrease
• Diastolic blood pressure: 1-2 mmHg decrease

These reductions may seem modest, but population studies demonstrate that every 2 mmHg reduction in systolic blood pressure reduces cardiovascular mortality by approximately 7% and stroke risk by 10%.

The mechanism of blood pressure reduction with GLP-1 medications involves natriuresis (increased sodium excretion by the kidneys), improved endothelial function in blood vessels, reduced sympathetic nervous system activity, and decreased arterial stiffness.

Lipid Profile Improvement

GLP-1 medications produce favorable changes in cholesterol levels and other lipid parameters:

Typical lipid changes with semaglutide:

• Total cholesterol: 2-6% reduction
• LDL cholesterol (the “bad” cholesterol): 3-7% reduction
• Triglycerides: 10-15% reduction
• HDL cholesterol (the “good” cholesterol): 1-3% increase

While these lipid improvements are less dramatic than those achieved with statins, they contribute to overall cardiovascular risk reduction. The mechanism involves enhanced clearance of triglyceride-rich lipoproteins and reduced hepatic production of VLDL particles.

Anti-Inflammatory Effects

Chronic low-grade inflammation plays a central role in atherosclerosis development and plaque instability. GLP-1 medications reduce multiple inflammatory markers:

C-reactive protein (CRP): A marker of systemic inflammation, CRP levels decrease 20-40% with GLP-1 therapy. Lower CRP correlates with reduced cardiovascular event risk.

Inflammatory cytokines: Levels of IL-6, TNF-alpha, and other pro-inflammatory molecules decrease with GLP-1 treatment, suggesting reduced vascular inflammation.

Adipokine profile: GLP-1 medications shift the balance from pro-inflammatory adipokines (like leptin and resistin) toward anti-inflammatory adiponectin, creating a less inflammatory metabolic environment.

The mechanism involves both direct effects (GLP-1 receptors on immune cells and vascular endothelium) and indirect effects through weight loss and improved metabolic health.

Direct Vascular and Cardiac Effects

Beyond metabolic improvements, GLP-1 receptors exist in the cardiovascular system itself, suggesting direct protective effects on blood vessels and the heart.

Endothelial function improvement: The endothelium (inner lining of blood vessels) plays crucial roles in regulating blood flow, preventing clot formation, and resisting atherosclerosis. GLP-1 medications improve endothelial function by increasing nitric oxide production, reducing oxidative stress, and decreasing endothelial cell inflammation.

Reduced arterial stiffness: With aging and cardiovascular disease, arteries become stiffer, increasing blood pressure and cardiac workload. GLP-1 medications reduce arterial stiffness, improving vascular compliance.

Cardioprotection during ischemia: Animal studies suggest GLP-1 protects heart muscle during periods of reduced blood flow (ischemia), potentially limiting damage during heart attacks. The clinical relevance of this finding remains under investigation.

Reduced atherosclerotic plaque inflammation: Imaging studies using advanced techniques like FDG-PET show reduced inflammation in atherosclerotic plaques after GLP-1 treatment, suggesting stabilization of vulnerable plaques that could rupture and cause heart attacks.

Glucose Control and Reduction of Hyperglycemia

For patients with type 2 diabetes, improved blood sugar control contributes to cardiovascular benefit. Chronic hyperglycemia damages blood vessels through multiple mechanisms:

Advanced glycation end products (AGEs): Excess glucose binds to proteins, forming AGEs that stiffen blood vessels and promote inflammation.

Oxidative stress: High blood sugar increases production of reactive oxygen species that damage vascular endothelium.

Microvascular damage: Hyperglycemia damages small blood vessels, contributing to kidney disease, retinopathy, and neuropathy, all of which increase cardiovascular risk.

By lowering HbA1c by 1-2%, GLP-1 medications reduce these hyperglycemia-mediated mechanisms of cardiovascular damage.

Kidney Protection

The cardiovascular and renal systems are intimately connected—kidney disease dramatically increases cardiovascular risk. GLP-1 medications protect the kidneys through hemodynamic effects (improved kidney blood flow and reduced intraglomerular pressure), reduced albuminuria (protein in urine, a marker of kidney damage), anti-inflammatory effects in kidney tissue, and blood pressure reduction.

In the SUSTAIN-6 trial, Ozempic reduced the risk of new or worsening nephropathy by 36%. This kidney protection translates to reduced cardiovascular risk, as even modest declines in kidney function significantly increase the likelihood of heart disease.

For these patients, GLP-1 medications represent secondary prevention—preventing recurrent cardiovascular events in patients who have already experienced one. The absolute benefit is substantial because this population has higher baseline risk.

Patients with Type 2 Diabetes and Multiple Cardiovascular Risk Factors

The SUSTAIN-6 trial enrolled patients with type 2 diabetes at high cardiovascular risk, defined as established cardiovascular disease, chronic kidney disease, or age 60+ with cardiovascular risk factors (hypertension, dyslipidemia, smoking, or obesity).

This population also showed clear benefit from Ozempic, with 26% reduction in cardiovascular events. For patients with diabetes but without established cardiovascular disease, this represents primary prevention—preventing first cardiovascular events in high-risk individuals.

Cardiovascular risk factors that increase benefit likelihood:

• Hypertension (blood pressure ≥140/90 mmHg or on antihypertensive medication)
• Dyslipidemia (LDL cholesterol ≥130 mg/dL, HDL cholesterol <40 mg/dL in men or <50 mg/dL in women, triglycerides ≥150 mg/dL)
• Smoking (current or recent history)
• Family history of premature cardiovascular disease (first-degree relative with heart attack or stroke before age 55 in men or 65 in women)
• Chronic kidney disease (estimated GFR <60 mL/min or significant albuminuria)
• Obesity (BMI ≥30 kg/m²)
• Duration of diabetes >10 years

The more of these risk factors present, the higher the absolute cardiovascular risk and the greater the absolute benefit from GLP-1 therapy.

Patients with Obesity and Metabolic Syndrome

Metabolic syndrome—a constellation of hypertension, insulin resistance, dyslipidemia, and abdominal obesity—dramatically increases cardiovascular risk even in the absence of diagnosed diabetes.

The SELECT trial demonstrated that patients with obesity and established cardiovascular disease benefit from Wegovy regardless of diabetes status. This suggests that the cardiovascular benefits extend beyond glucose control to other mechanisms.

Metabolic syndrome criteria (3 or more of the following):

• Waist circumference ≥40 inches in men or ≥35 inches in women
• Triglycerides ≥150 mg/dL
• HDL cholesterol <40 mg/dL in men or <50 mg/dL in women
• Blood pressure ≥130/85 mmHg
• Fasting glucose ≥100 mg/dL

Patients meeting metabolic syndrome criteria who also have obesity are strong candidates for GLP-1 therapy for cardiovascular protection, particularly if they have other risk factors or family history of early cardiovascular disease.

Patients with Heart Failure and Preserved Ejection Fraction

Emerging research suggests GLP-1 medications may benefit patients with heart failure with preserved ejection fraction (HFpEF), a condition where the heart pumps normally but doesn't relax and fill adequately.

HFpEF strongly associates with obesity and metabolic dysfunction. Weight loss improves symptoms and exercise capacity in these patients. While dedicated heart failure trials of GLP-1 medications are ongoing, observational data and small studies suggest benefit.

Patients with HFpEF and obesity may be candidates for GLP-1 therapy, particularly if they also have diabetes or other cardiovascular risk factors.

Cardiovascular Considerations in GLP-1 Treatment Decisions

For patients and providers evaluating whether GLP-1 medications are appropriate, several cardiovascular-specific factors deserve consideration.

Calculating Absolute Cardiovascular Risk

The absolute benefit of GLP-1 therapy depends on baseline cardiovascular risk. A 20% relative risk reduction produces different absolute benefits depending on starting risk:

High baseline risk (10% chance of cardiovascular event over 3 years):

• With GLP-1: 8% risk (10% × 0.8 = 8%)
• Absolute risk reduction: 2% (10% – 8%)
• Number needed to treat: 50 patients for 3 years to prevent 1 event

Low baseline risk (2% chance of cardiovascular event over 3 years):

• With GLP-1: 1.6% risk (2% × 0.8 = 1.6%)
• Absolute risk reduction: 0.4% (2% – 1.6%)
• Number needed to treat: 250 patients for 3 years to prevent 1 event

This demonstrates why targeting high-risk patients maximizes the benefit of GLP-1 therapy. The SELECT trial's number needed to treat of 67 reflects the high baseline risk of the enrolled population (previous cardiovascular events).

For lower-risk patients, the absolute cardiovascular benefit is smaller, though weight loss and metabolic benefits may still justify treatment.

Cardiovascular Benefits Timeline

The cardiovascular benefits of GLP-1 medications emerge gradually rather than immediately. Understanding this timeline helps set appropriate expectations.

0-3 months: Metabolic improvements begin (weight loss, blood pressure reduction, improved insulin sensitivity). Cardiovascular benefit during this period is minimal.

3-12 months: Weight loss accelerates, reaching maximum rate. Blood pressure and lipid improvements plateau. Early cardiovascular benefit emerges.

12-36 months: Cardiovascular benefit becomes fully evident. The SELECT trial showed benefit emerging within the first year and persisting throughout the 40-month median follow-up.

This timeline suggests that GLP-1 therapy should be viewed as a long-term cardiovascular risk reduction strategy rather than acute intervention. Patients must commit to sustained treatment to realize cardiovascular benefits.

Combining GLP-1 Medications with Other Cardiovascular Therapies

GLP-1 medications complement rather than replace standard cardiovascular therapies. Optimal cardiovascular protection involves multi-faceted risk factor management.

Statins: GLP-1 medications and statins work through different mechanisms and should be used together in patients with elevated LDL cholesterol or established cardiovascular disease. There's no interaction between these drug classes.

Antihypertensive medications: GLP-1 medications lower blood pressure modestly, but most patients with hypertension still require dedicated antihypertensive therapy. Combination treatment is safe and effective. As GLP-1 therapy produces weight loss and blood pressure reduction, antihypertensive doses may need adjustment to avoid excessive blood pressure lowering.

Antiplatelet therapy: Patients with established cardiovascular disease should continue aspirin or other antiplatelet medications along with GLP-1 therapy. These medications prevent clot formation through complementary mechanisms.

Diabetes medications: For patients with type 2 diabetes, GLP-1 medications can be combined with metformin, SGLT2 inhibitors, and other diabetes therapies. Careful coordination is needed when combining with insulin or sulfonylureas to avoid hypoglycemia.

SGLT2 inhibitors: This newer diabetes medication class also shows cardiovascular and kidney benefits. Some evidence suggests complementary effects when combined with GLP-1 medications, though cost and insurance coverage may limit use of both medication classes simultaneously.

The goal is comprehensive risk factor control: LDL cholesterol to target (<70 mg/dL for very high-risk patients), blood pressure controlled (<130/80 mmHg for most patients), HbA1c at goal (<7% for most patients with diabetes, more stringent targets for some), weight loss for patients with obesity, smoking cessation, and appropriate use of aspirin and other antiplatelet therapy.

GLP-1 medications address multiple components of this comprehensive approach but don't eliminate the need for other evidence-based therapies.

Cardiovascular Safety Considerations

While GLP-1 medications reduce overall cardiovascular risk, they do carry some cardiovascular-related side effects and monitoring considerations.

Heart Rate Effects

GLP-1 medications slightly increase heart rate, typically by 2-4 beats per minute. This effect persists throughout treatment and doesn't appear to attenuate over time.

The mechanism likely involves autonomic nervous system effects, possibly through reduced parasympathetic tone or increased sympathetic activity. In clinical trials, this modest heart rate increase hasn't translated to adverse cardiovascular outcomes—in fact, cardiovascular benefits have been demonstrated despite the higher heart rate.

Most patients don't notice the heart rate increase subjectively. However, patients with pre-existing tachyarrhythmias or those sensitive to heart rate changes should be aware of this effect.

Potential Dehydration and Hemodynamic Effects

The gastrointestinal side effects of GLP-1 medications—particularly nausea, vomiting, and diarrhea—can cause dehydration. For patients on certain cardiovascular medications, dehydration creates specific risks:

ACE inhibitors and ARBs: Dehydration combined with these blood pressure medications can worsen kidney function. Patients experiencing significant GI side effects should maintain adequate hydration and may need temporary dose reduction of ACE inhibitors or ARBs.

Diuretics: The combination of diuretic medications and GLP-1-related fluid losses can lead to excessive volume depletion and electrolyte abnormalities. Close monitoring is warranted, particularly during dose escalation periods.

Orthostatic hypotension: Dehydration combined with blood pressure medications can cause excessive blood pressure drops when standing, increasing fall risk. This is particularly relevant for older patients or those on multiple blood pressure medications.

Drug Interactions and Medication Adjustments

GLP-1 medications slow gastric emptying, which can affect the absorption of oral medications. This is particularly relevant for certain cardiovascular drugs:

Oral anticoagulants: Medications like warfarin require consistent absorption for stable anticoagulation. The altered gastric emptying with GLP-1 therapy might theoretically affect warfarin absorption, though clinical significance appears minimal. More frequent INR monitoring may be prudent when initiating GLP-1 therapy in patients on warfarin.

Narrow therapeutic index medications: Drugs requiring precise blood levels (like digoxin) might be affected by altered absorption kinetics. Monitoring drug levels after starting GLP-1 therapy is reasonable for these medications.

For most cardiovascular medications, including statins, beta-blockers, and antiplatelet agents, no significant interactions occur with GLP-1 therapy.

The Role of Telehealth in Accessing GLP-1 Cardiovascular Protection

For patients with cardiovascular disease or high cardiovascular risk, accessing GLP-1 medications often involves coordination between cardiologists, endocrinologists, and primary care providers. Telehealth platforms have emerged as a convenient access point, but cardiovascular patients have specific considerations.

Advantages of Telehealth for Cardiovascular Patients

Improved access: Patients in rural areas or those with mobility limitations from cardiovascular disease can access specialist evaluation without travel.

Coordination of care: Quality telehealth platforms facilitate communication between the GLP-1 prescriber and your cardiovascular care team.

Convenience: For patients managing multiple chronic conditions, telehealth reduces the burden of frequent in-person appointments.

Medication delivery: Home delivery of GLP-1 medications is particularly valuable for patients with limited mobility or transportation challenges.

Critical Considerations for Cardiovascular Patients Using Telehealth

Comprehensive medical history review: Your telehealth provider must have complete information about your cardiovascular history, including specific diagnoses, procedures (CABG, stenting), current symptoms, and recent cardiovascular events.

Current medication review: Telehealth providers need a complete list of your cardiovascular medications to assess for potential interactions and dose adjustments needed when starting GLP-1 therapy.

Blood pressure and heart rate monitoring: You'll need capability to monitor blood pressure and heart rate at home so your provider can track the effects of GLP-1 therapy on these parameters.

Communication with your cardiologist: The telehealth provider should be willing to communicate with your cardiologist or other cardiovascular specialists to coordinate care. Ask whether they will send treatment summaries to your other providers.

Handling cardiovascular emergencies: Understand that telehealth providers are not appropriate for acute cardiovascular symptoms. Chest pain, severe shortness of breath, or other concerning symptoms require in-person evaluation or emergency care, not telehealth consultation.

Programs like MultiMedRx offer telehealth access to GLP-1 medications with licensed healthcare providers who can evaluate cardiovascular history, coordinate with existing care teams, and provide ongoing monitoring. The $100 fully refundable consultation allows patients to determine if GLP-1 therapy is appropriate for their cardiovascular risk profile without financial commitment if they're not candidates.

Schedule a cardiovascular-informed consultation or call 800.787.9659 to discuss GLP-1 options for cardiovascular protection.

Future Directions: What's Coming in GLP-1 Cardiovascular Research

The cardiovascular story of GLP-1 medications continues to evolve as new trials report results and additional indications emerge.

Tirzepatide Cardiovascular Outcomes

The SURPASS-CVOT trial is evaluating tirzepatide's cardiovascular effects in patients with type 2 diabetes at high cardiovascular risk. Given tirzepatide's superior weight loss and glycemic control compared to semaglutide, there's speculation it might show even greater cardiovascular benefit. Results expected in 2025-2026 will clarify this question.

Heart Failure Trials

Dedicated trials are evaluating GLP-1 medications specifically for heart failure with preserved ejection fraction (HFpEF). The STEP-HFpEF trial showed Wegovy improved symptoms, exercise capacity, and quality of life in patients with HFpEF and obesity. Longer-term trials will determine if these symptom improvements translate to reduced heart failure hospitalizations and mortality.

Combination Therapy Studies

Research is exploring optimal combinations of cardiovascular medications. Questions include: Do GLP-1 medications plus SGLT2 inhibitors provide additive cardiovascular benefit beyond either medication alone? What's the optimal combination of lipid-lowering therapies (statins, PCSK9 inhibitors, ezetimibe) with GLP-1 medications? Can GLP-1 medications enhance benefits of cardiac rehabilitation programs?

Cardiovascular Imaging Studies

Advanced imaging techniques are revealing how GLP-1 medications affect atherosclerotic plaques, cardiac structure, and vascular function. These mechanistic studies help explain the cardiovascular benefits observed in clinical trials and may identify biomarkers predicting which patients will benefit most.

Making the Decision: Is GLP-1 Therapy Right for Your Cardiovascular Health?

For patients with cardiovascular disease or high cardiovascular risk, GLP-1 medications represent an evidence-based addition to comprehensive cardiovascular risk reduction strategies.

GLP-1 therapy makes sense when:

• You have established cardiovascular disease (previous heart attack, stroke, coronary disease, peripheral artery disease) and obesity or overweight
• You have type 2 diabetes with multiple cardiovascular risk factors
• You have metabolic syndrome with obesity and family history of premature cardiovascular disease
• Your cardiovascular risk is elevated based on risk calculation tools
• You can commit to long-term treatment (benefits emerge over months to years)
• Cost and access are manageable through insurance coverage or affordable cash-pay options

Additional evaluation may be needed if:

• You have heart failure with reduced ejection fraction (standard GLP-1 trials excluded this population, though newer evidence is emerging)
• You have severe kidney disease (dosing adjustments or alternative medications may be needed)
• You're taking multiple medications with potential interactions
• You have conditions that might complicate GLP-1 therapy (severe gastroparesis, inflammatory bowel disease)

Work with your cardiovascular care team to determine if GLP-1 medications fit into your overall cardiovascular risk reduction strategy. The medications are powerful tools but work best as part of comprehensive management including optimal blood pressure control, lipid management, smoking cessation, healthy diet, regular physical activity, and appropriate use of antiplatelet therapy.

The cardiovascular benefits of GLP-1 medications are real, substantial, and backed by rigorous clinical trial evidence. For the right patients, these medications offer meaningful reduction in the risk of heart attack, stroke, and cardiovascular death—outcomes that matter most.

Important Safety Information

GLP-1 medications may cause serious side effects, including possible thyroid tumors including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath, as these may be symptoms of thyroid cancer.

Do not use GLP-1 medications if you or any of your family have ever had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use if you have had a serious allergic reaction to semaglutide, tirzepatide, or any ingredients in these medications.

Before using GLP-1 medications, tell your healthcare provider about all medical conditions, including if you have or have had problems with your pancreas, kidneys, liver, or stomach, or have a history of diabetic retinopathy. Tell your provider if you are pregnant, breastfeeding, or plan to become pregnant.

GLP-1 medications may cause serious side effects including inflammation of the pancreas (pancreatitis), gallbladder problems, kidney problems, serious allergic reactions, low blood sugar, changes in vision, and increased heart rate. The most common side effects include nausea, vomiting, diarrhea, constipation, stomach pain, headache, and fatigue.

Weight loss results are not guaranteed and individual results vary. All medications are prescription-only and provided only after evaluation by a licensed healthcare provider. This information does not constitute medical advice. Consult a licensed healthcare provider for personalized medical guidance.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.